GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (LSE:TCF) » Definitions » Cash Conversion Cycle

TheraCryf (LSE:TCF) Cash Conversion Cycle : 0.00 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is TheraCryf Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

TheraCryf's Days Sales Outstanding for the six months ended in Mar. 2024 was 0.
TheraCryf's Days Inventory for the six months ended in Mar. 2024 was .
TheraCryf's Days Payable for the six months ended in Mar. 2024 was .
Therefore, TheraCryf's Cash Conversion Cycle (CCC) for the six months ended in Mar. 2024 was 0.00.


TheraCryf Cash Conversion Cycle Historical Data

The historical data trend for TheraCryf's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Cash Conversion Cycle Chart

TheraCryf Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 140.80 373.76

TheraCryf Semi-Annual Data
Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 116.02 183.88 -

Competitive Comparison of TheraCryf's Cash Conversion Cycle

For the Biotechnology subindustry, TheraCryf's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TheraCryf's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TheraCryf's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where TheraCryf's Cash Conversion Cycle falls into.



TheraCryf Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

TheraCryf's Cash Conversion Cycle for the fiscal year that ended in Mar. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=373.76+-
=373.76

TheraCryf's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+-
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TheraCryf  (LSE:TCF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


TheraCryf Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of TheraCryf's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


TheraCryf (LSE:TCF) Business Description

Traded in Other Exchanges
Address
Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG
Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (LSE:TCF) Headlines

From GuruFocus

Tcf Financial Corp (TCF) EVP, CFO Brian W Maass Sold $887,338 of Shares

By GuruFocus Research GuruFocus Editor 02-05-2021

Lindsay Yousif Named TCF Bank's Chief Compliance Officer

By Business Wire Business Wire 11-19-2020

TCF National Bank Acquires BB&T Commercial Equipment Capital, Corp.

By Business Wire Business Wire 02-01-2021

New TCF Banking Center Opens on West Seven Mile in Detroit

By Business Wire Business Wire 02-26-2021